This is a modified schedule developed a few years ago that had results compared to the FDA approved schedule. This is summarized below from the attached medical journal article that reviewed the procedures. It makes sense to me, though my urologist is following the approved traditional schedule and that seems to be working for me, albeit with more pain etc. than you would have with this shortened schedule. I would not discount your doctor's approach, he may just be more progressive than my (and most) doctors.
"More recently, Abdel Raheem et al [66] evaluated the efficacy and safety of CCH administration using a modified and shortened treatment protocol in 53 patients at a single center. In their shortened protocol, each cycle consists
of only one injection with a larger dose of CCH (0.9 mg; whole vial), rather than two injections of the dose (0.58 mg each) outlined by Gelbard et al [6,59,61,62] in earlier studies (Fig. 1). This method allows higher concentrations
of CCH to be delivered to the
plaque while limiting the inflammatory changes that occur with more injections. Furthermore, limiting the frequency of injections in the modified protocol and having patients complete the modeling themselves at home, allows patients to
complete treatment in only four patient visits over a 12-week period (Table 1). This undoubtedly improves compliance and reduces costs associated with CCH treatment. More importantly however, this shortened modified protocol demonstrated a mean curvature reduction
of −17.4° (−31.4%) from baseline. This is comparable to the results obtained in the IMPRESS trials, which yielded mean curvature reduction of −17° (−34%) from baseline [66]. Moreover, there was an improvement in each of the IIEF questionnaire domains, all 3 PDQ domains,
and the global assessment of the PDQ."
The original paper is here, but I do not have a copy of it:
Abdel Raheem A, Capece M, Kalejaiye O, Abdel-Raheem T, Falcone M, Johnson M, et al. Safety and effectiveness of
collagenaseclostridium histolyticum in the treatment of Peyronie’s disease using a new modified shortened protocol. BJU Int 2017. doi: 10.1111/bju.13932